Even with treatments that target a known resistance pattern, an additional genetic mutation can render the treatment obsolete or ineffective, notably demonstrated by the acquired EGFR C797S mutation in NSCLC with preexisting EGFR T790M mutation [93]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.